S
Sébastien Lacroix-Desmazes
Researcher at University of Paris
Publications - 256
Citations - 10130
Sébastien Lacroix-Desmazes is an academic researcher from University of Paris. The author has contributed to research in topics: Antibody & Immune system. The author has an hindex of 53, co-authored 249 publications receiving 9254 citations. Previous affiliations of Sébastien Lacroix-Desmazes include Pierre-and-Marie-Curie University & Paris Descartes University.
Papers
More filters
Journal ArticleDOI
Cutting Edge: Human CD4+CD25+ T Cells Restrain the Maturation and Antigen-Presenting Function of Dendritic Cells
Namita Misra,Jagadeesh Bayry,Sébastien Lacroix-Desmazes,Michel D. Kazatchkine,Srini V. Kaveri +4 more
TL;DR: It is shown that regulatory T cells render the DC inefficient as APCs despite prestimulation with CD40 ligand, and this effect was marginally reverted by neutralizing Abs to TGF-β and reduced expression of costimulatory molecules in DC.
Journal ArticleDOI
Self-reactive antibodies (natural autoantibodies) in healthy individuals
Sébastien Lacroix-Desmazes,Srini V. Kaveri,Luc Mouthon,Ahidjo Ayouba,Evelyne Malanchère,Antonio Coutinho,Michel D. Kazatchkine +6 more
TL;DR: The current knowledge on the physicochemical and functional properties of NAA in man, and the use of N AA for therapeutic intervention is focused on.
Journal ArticleDOI
Inhibition of maturation and function of dendritic cells by intravenous immunoglobulin
Jagadeesh Bayry,Sébastien Lacroix-Desmazes,Cédric Carbonneil,Namita Misra,Vladimira Donkova,Anastas Pashov,Alain Chevailler,Luc Mouthon,Bernard Weill,Patrick Bruneval,Michel D. Kazatchkine,Srini V. Kaveri +11 more
TL;DR: It is shown that IVIg inhibits the differentiation and maturation of DCs in vitro and abrogates the capacity of mature DC to secrete interleukin-12 (IL-12) on activation while enhancing IL-10 production.
Journal ArticleDOI
Expansion of CD4+CD25+ regulatory T cells by intravenous immunoglobulin: a critical factor in controlling experimental autoimmune encephalomyelitis.
Amal Ephrem,Souleima Chamat,Catherine Miquel,Sylvain Fisson,Sylvain Fisson,Sylvain Fisson,Luc Mouthon,Giuseppina Caligiuri,Giuseppina Caligiuri,Giuseppina Caligiuri,Sandrine Delignat,Sandrine Delignat,Sandrine Delignat,Sriramulu Elluru,Sriramulu Elluru,Sriramulu Elluru,Jagadeesh Bayry,Jagadeesh Bayry,Jagadeesh Bayry,Sébastien Lacroix-Desmazes,Sébastien Lacroix-Desmazes,Sébastien Lacroix-Desmazes,José L. Cohen,José L. Cohen,Benoît L. Salomon,Benoît L. Salomon,Michel D. Kazatchkine,Michel D. Kazatchkine,Michel D. Kazatchkine,Srini V. Kaveri,Srini V. Kaveri,Srini V. Kaveri,Namita Misra,Namita Misra,Namita Misra +34 more
TL;DR: It is shown that prophylactic infusion of IVIg prevents the development of experimental autoimmune encephalomyelitis (EAE), an accepted animal model for multiple sclerosis (MS), and the protection was Treg-mediated because IVIG failed to protect against EAE in mice that were depleted of the Treg population.
Journal ArticleDOI
Intravenous Immunoglobulin: An Update on the Clinical Use and Mechanisms of Action
Vir Singh Negi,Sriramulu Elluru,Sophie Sibéril,Stéphanie Graff-Dubois,Luc Mouthon,Michel D. Kazatchkine,Sébastien Lacroix-Desmazes,Jagadeesh Bayry,Srini V. Kaveri +8 more
TL;DR: Initially used as a replacement therapy for immunodeficiency diseases, intravenous immunoglobulin (IVIg) is now widely used for a number of autoimmune and inflammatory diseases.